Moderna Stock Climbs on FDA Emergency Use News

Earlier this month, the company requested full FDA approval for the vaccine in teens

Assistant Editor
Jun 10, 2021 at 10:05 AM
facebook twitter linkedin

Moderna Inc (NASDAQ:MRNA) is back in the spotlight today, after the biotech concern asked the U.S. Food and Drug Administration (FDA) to approve the emergency use of its Covid-19 vaccine mRNA in adolescents ages 12 to 17. On May 25, Moderna said its vaccine was 100% effective in a study of adolescents in that age range -- which included more than 3,700 participants -- and saw no new Covid-19 cases observed after two doses of the vaccine. MRNA is responding well to the news, last seen 1.9% higher to trade at $221.48.

The company made headlines earlier this month after applying for full FDA approval for the vaccine, and the security went on to notch a new record high of $227.71 by June 7. Carving out a channel of higher highs all year, the shares' 10-day moving average has moved in to guide the shares higher in recent months. Now up an impressive 108.6% year-to-date, MRNA is on track for its fourth straight weekly win.

Moderna stock is sporting attractively priced premiums at the moment, too. The stock's Schaeffer's Volatility Index (SVI) of 63% stands higher than just 10% of all other readings from the past year. In simpler terms, option players are pricing in low volatility expectations right now.

What’s more, its Schaeffer's Volatility Scorecard (SVS) sits at a relatively high 81 out of a possible 100, indicating that the stock has managed to exceed these volatility expectations over the last 12 months.

Make the Most of the next Expiration Week Countdown!


Special Offers from Schaeffer's Trading Partners